Ligand Pharmaceuticals (LGND) Accumulated Expenses (2010 - 2026)

Ligand Pharmaceuticals has disclosed Accumulated Expenses across 17 years of filings, most recently posting $31.8 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $31.8 million, up 35.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $31.8 million (up 35.3% YoY), and the FY2025 annual result was $31.5 million, up 12.71% from the prior year.
• Accumulated Expenses came in at $31.8 million for Q1 2026 at Ligand Pharmaceuticals, up from $31.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $31.8 million in Q1 2026 to a low of $7.3 million in Q2 2023.
• The 5-year median for Accumulated Expenses is $15.7 million (2022), against an average of $18.1 million.
• Across the five-year window, Accumulated Expenses tumbled 49.89% in 2023 and soared 123.84% in 2024, its largest moves.
• Ligand Pharmaceuticals' Accumulated Expenses stood at $15.7 million in 2022, then slipped by 20.5% to $12.5 million in 2023, then soared by 123.84% to $27.9 million in 2024, then advanced by 12.71% to $31.5 million in 2025, then increased by 1.25% to $31.8 million in 2026.
• The last three Accumulated Expenses figures came in at $31.8 million (Q1 2026), $31.5 million (Q4 2025), and $24.1 million (Q3 2025), per Business Quant data.